Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 14 November 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The loss was smaller than forecast because revenue from supplying cosmetic raw materials to Albion Co., Ltd. exceeded the initial expectations, research and development expenses for the NANO MRNA business were lower than initially expected as clinical trials progressed, and no M&A expenses were incurred during the fiscal year, among other factors.
| Item | Details |
|---|---|
| Net Sales | ¥156 million → ¥174 million（+11.7%） |
| Operating profit | ¥-1,060 million → ¥-965 million |
| Ordinary income | ¥-1,002 million → ¥-866 million |
| Profit attributable to owners of the parent | ¥-1,061 million → ¥-943 million |
| Net income per share | -14.72 yen → -12.9 yen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 14 November 2025 |
| Previous-period results | Sales: ¥108 million; operating loss: ¥755 million; ordinary loss: ¥687 million; net loss attributable to owners of the parent: ¥835 million; loss per share: ¥11.85 |
| Reason for the revision | The loss was smaller than forecast because revenue from supplying cosmetic raw materials to Albion Co., Ltd. exceeded the initial expectations, research and development expenses for the NANO MRNA business were lower than initially expected as clinical trials progressed, and no M&A expenses were incurred during the fiscal year, among other factors. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This was because revenue from supplying cosmetic raw materials to Albion Co., Ltd. exceeded expectations, while research and development expenses for the NANO MRNA business were lower than expected as clinical trials progressed, and no M&A expenses were incurred during the fiscal year.